• Reuters3 days ago

    Teva, Allergan win U.S. antitrust approval for generics deal

    Teva Pharmaceutical Industries Ltd won U.S. antitrust approval to purchase Allergan Plc's generics business, after agreeing to divest 79 generic drugs to rival firms, the Federal Trade Commission said on Wednesday. The $40.5 billion deal, which was announced in July 2015, solidifies Teva's position as the world's No. 1 maker of generics while freeing Allergan to focus on branded drugs. Teva will sell rights and assets related to the 79 pharmaceutical products to 11 rival firms, marking the largest ever drug divestiture order in an FTC pharmaceutical merger case, the commission said in a statement.

  • TheStreet.com9 days ago

    It's Time to Sell These 5 Big Stocks This Summer

    Owning these stocks could be toxic to your portfolio.